RITUXIMAB, PLERIXAFOR, OTL-103, FLUDARABINE PHOSPHATE, LENOGRASTIM, BUSULFAN
OTL-103-4
Phase 3 small_molecule active
Quick answer
RITUXIMAB, PLERIXAFOR, OTL-103, FLUDARABINE PHOSPHATE, LENOGRASTIM, BUSULFAN for Wiskott-Aldrich Syndrome is a Phase 3 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- Wiskott-Aldrich Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active